

20190338	G	Greenbriar Equity Fund IV, L.P.; BDP International, Inc.; Greenbriar Equity Fund IV, L.P.
20190360	G	Altair Engineering Inc.; Datawatch Corporation; Altair Engineering Inc.
11/28/2018		
20190296	G	KK GP; Agnaten SE; KK GP.
20190327	G	William Goldring; Diageo plc; William Goldring.
20190329	G	Vista Equity Partners Fund VI, L.P.; Apptio, Inc.; Vista Equity Partners Fund VI, L.P.
11/29/2018		
20190311	G	IFM Global Infrastructure Fund; Vitol Holding B.V.; IFM Global Infrastructure Fund.
20190312	G	Vitol Investment Partnership II Limited; VJVCo; Vitol Investment Partnership II Limited.
20190336	G	Hexagon Composites ASA; AFS Holdco, LLC; Hexagon Composites ASA.
20190339	G	Arcosa, Inc.; H.I.G. Capital Partners IV, L.P.; Arcosa, Inc.
20190345	G	Audax Private Equity Fund V–A, L.P.; 3RC/Phoenix Investment, LLC; Audax Private Equity Fund V–A, L.P.
20190212	G	Golden Gate Capital Opportunity Fund. L.P.; VeriSign, Inc.; Golden Gate Capital Opportunity Fund. L.P.
20190332	G	Richard A. Robinson & Betti G. Robinson; O'Neal Industries, Inc.; Richard A. Robinson & Betti G. Robinson.
20190347	G	China National Chemical Corporation; Bonide Products, Inc.; China National Chemical Corporation.
20190350	G	AIA Oratam Sidecar LLC; Hudson Transmission Partners, LLC; AIA Oratam Sidecar LLC.
20190351	G	Mr. Cooper Group Inc.; Evan M. Stone; Mr. Cooper Group Inc.
20190352	G	Sun Capital Partners VI, LP.; Southfield Tier One Investment LP; Sun Capital Partners VI, LP.
20190353	G	Chesapeake Energy Corporation; WildHorse Resource Development Corporation; Chesapeake Energy Corporation.
20190355	G	Leggett & Platt Incorporated; Elite Comfort Solutions LP; Leggett & Platt Incorporated.
20190357	G	Sentinel Capital Partners VI, L.P.; Irving Place Capital Partners III SPV, L.P.; Sentinel Capital Partners VI, L.P.
20190359	G	Linden Capital Partners IV–A LP; Arlington Capital Partners III, L.P.; Linden Capital Partners IV–A LP.
20190367	G	Sycamore Partners III, L.P.; Newell Brands Inc.; Sycamore Partners III, L.P.
20190375	G	Klaus-Michael Kuhne; The Resolute Fund III, L.P.; Klaus-Michael Kuhne.
20190377	G	Chatchaval Jiaravanon; Meredith Corporation; Chatchaval Jiaravanon.
20190388	G	AIPCF VI Indirect Investor AIV LP; Armstrong Flooring, Inc.; AIPCF VI Indirect Investor AIV LP.
20190389	G	American Industrial Partners Capital Fund V, L.P.; Elkay Manufacturing Company; American Industrial Partners Capital Fund V, L.P.
20190390	G	Open Text Corporation; LiaisonTechnologies, Inc.; Open Text Corporation.
20190396	G	Prime Communications, L.P.; GameStop Corp.; Prime Communications, L.P.

FOR FURTHER INFORMATION CONTACT:

Theresa Kingsberry, Program Support Specialist, Federal Trade Commission Premerger Notification Office, Bureau of Competition, Room CC–5301, Washington, DC 20024, (202) 326–3100.

By direction of the Commission.

April J. Tabor,
Acting Secretary.

[FR Doc. 2019–07735 Filed 4–17–19; 8:45 am]

BILLING CODE 6750–01–P

DEPARTMENT OF DEFENSE**GENERAL SERVICES
ADMINISTRATION****NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION**

[OMB Control No. 9000–0070; Docket No. 2019–0003; Sequence No. 18]

Information Collection; Payments

AGENCY: Department of Defense (DOD), General Services Administration (GSA), and National Aeronautics and Space Administration (NASA).

ACTION: Notice and request for comments.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995 and the Office of Management and Budget

(OMB) regulations, the FAR Council invites the public to comment upon a renewal regarding advanced payments.

DATES: *Submit comments on or before:* June 17, 2019.

ADDRESSES: The FAR Council invites interested persons to submit comments on this collection by either of the following methods:

- *Federal eRulemaking Portal:* This website provides the ability to type short comments directly into the comment field or attach a file for lengthier comments. Go to <http://www.regulations.gov> and follow the instructions on the site.
- *Mail:* General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW, Washington, DC 20405. ATTN: Ms. Mandell/IC 9000–0070, Payments.

Instructions: Please submit comments only and cite Information Collection 9000–0070, Payments, in all correspondence related to this collection. Comments received generally will be posted without change to <http://www.regulations.gov>, including any personal and/or business confidential information provided. To confirm receipt of your comment(s), please check www.regulations.gov, approximately two-to-three days after submission to verify posting (except allow 30 days for posting of comments

submitted by mail). This information collection is pending at the FAR Council.

FOR FURTHER INFORMATION CONTACT: Mr. Kevin Funk, Procurement Analyst, at telephone 202–357–5805, or via email at kevin.funk@gsa.gov.

SUPPLEMENTARY INFORMATION:**A. Solicitation of Public Comment**

Written comments and suggestions from the public should address one or more of the following four points:

- (1) Evaluate whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- (3) Enhance the quality, utility, and clarity of the information to be collected; and
- (4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

B. Purpose

Firms performing under Federal contracts must provide adequate documentation to support requests for payment under these contracts. The documentation may range from a simple invoice to detailed cost data. The information is usually submitted once, at the end of the contract period or upon delivery of the supplies or services, but could be submitted more often depending on the payment schedule established under the contract (see Federal Acquisition Regulation (FAR) 52.232-1 through FAR 52.232-4, FAR 52.232-6, 52.232-7, and 52.232-10).

C. Annual Reporting Burden

Respondents: 1,724,163.
Responses per Respondent: 6.
Annual Responses: 10,344,978.
Hours per Response: 0.25.
Total Burden Hours: 2,586,245.
Obtaining Copies of Proposals:

Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW, Washington, DC 20405, at 202-501-4755. Please cite

OMB Control No. 9000-0070, Payments, in all correspondence.

Dated: April 15, 2019.

Janet Fry,
 Director, Federal Acquisition Policy Division,
 Office of Governmentwide Acquisition Policy,
 Office of Acquisition Policy, Office of
 Governmentwide Policy.

[FR Doc. 2019-07816 Filed 4-17-19; 8:45 am]

BILLING CODE 6820-EP-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-1020]

**Aurolife Pharma, LLC, et al.;
 Withdrawal of Approval of 31
 Abbreviated New Drug Applications**

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 31 abbreviated new drug applications (ANDAs) from

multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

DATES: Approval is withdrawn as of May 20, 2019.

FOR FURTHER INFORMATION CONTACT:

Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993-0002, 240-402-7945, Trang.Tran@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

Application No.	Drug	Applicant
ANDA 070470	Disopyramide Phosphate Capsules USP, Equivalent to (EQ) 100 milligrams (mg) base.	Aurolife Pharma, LLC, 279 Princeton Hightstown Rd., East Windsor, NJ 08520.
ANDA 070471	Disopyramide Phosphate Capsules USP, EQ 150 mg base	Do.
ANDA 070531	Clofibrate Capsules USP, 500 mg	Upsher-Smith Laboratories, LLC, 301 South Cherokee St., Denver, CO 80223.
ANDA 070797	Chlorpheniramine Maleate Extended-Release Capsules USP, 12 mg	Aurolife Pharma, LLC.
ANDA 070956	Diazepam Tablets USP, 10 mg	Halsey Drug Co., Inc., 1827 Pacific St., Brooklyn, NY 11233.
ANDA 071128	Haloperidol Tablets USP, 0.5 mg	Cycle Pharmaceuticals, Ltd., c/o Mapi USA, Inc., 2343 Alexandria Dr., Suite 100, Lexington, KY 40504.
ANDA 071129	Haloperidol Tablets USP, 1 mg	Do.
ANDA 071133	Haloperidol Tablets USP, 20 mg	Do.
ANDA 072394	Fenoprofen Calcium Capsules USP, EQ 200 mg base	Aurolife Pharma, LLC.
ANDA 072395	Fenoprofen Calcium Capsules USP, EQ 300 mg base	Do.
ANDA 072396	Fenoprofen Calcium Tablets USP, EQ 600 mg base	Do.
ANDA 072484	Trazodone Hydrochloride (HCl) Tablets USP, 50 mg	Do.
ANDA 074024	Ketoprofen Capsules, 50 mg and 75 mg	Do.
ANDA 074448	Flurbiprofen Tablets USP, 50 mg and 100 mg	Do.
ANDA 078300	Pamidronate Disodium for Injection USP, 30 mg/vial and 90 mg/vial	Mustafa Nevzat Ilac San. A.S. (MN Pharmaceuticals), c/o Sagent Pharmaceuticals, Inc., 1901 North Roselle Rd., suite 450, Schaumburg, IL 60195.
ANDA 080655	Meprobamate Tablets USP, 400 mg	Aurolife Pharma, LLC.
ANDA 083234	Glutethimide Tablets, 500 mg	Upsher-Smith Laboratories, LLC, 6701 Evenstad Dr. North, Maple Grove, MN 55369.
ANDA 084156	Pentobarbital Sodium Capsules, 100 mg	Warner-Lambert Company, 201 Tabor Rd., Morris Plains, NJ 07950.
ANDA 084674	Aminophylline Tables USP, 100 mg	Halsey Drug Co., Inc.
ANDA 085628	Sulfisoxazole Tablets USP, 500 mg	Aurolife Pharma, LLC.
ANDA 085813	Prednisone Tablets USP, 20 mg	Do.
ANDA 085844	Sulfamethoxazole Tablets USP, 500 mg	Do.
ANDA 085925	Amitriptyline HCl Tablets USP, 50 mg	Halsey Drug Co., Inc.
ANDA 085926	Amitriptyline HCl Tablets USP, 75 mg	Do.
ANDA 085927	Amitriptyline HCl Tablets USP, 100 mg	Do.
ANDA 089057	Cyproheptadine HCl Tablets USP, 4 mg	Do.
ANDA 089117	Hydroxyzine HCl Tablets USP, 25 mg	Do.
ANDA 089894	Quinidine Gluconate Extended-Release Tablets USP, 324 mg	Aurolife Pharma, LLC.
ANDA 089983	Prednisone Tablets USP, 10 mg	Do.